Open access · CC-BY
via OpenAlex
α-Synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson’s disease
Tracy A. Cole, Hien Tran Zhao, Timothy J. Collier, Ivette M. Sandoval, Caryl E. Sortwell, Kathy Steece‐Collier, Brian F. Daley, Alix Booms, Jack W. Lipton, Mackenzie Welch, Melissa Berman, Luke Jandreski, Danielle L. Graham, Andreas Weihofen, Stephanie L. Celano
JCI Insight · 2021 · ▲ 154 citations
Abstract
Parkinson's disease (PD) is a prevalent neurodegenerative disease with no approved disease-modifying therapies. Multiplications, mutations, and single nucleotide polymorphisms in the SNCA gene, encoding α-synuclein (aSyn) protein, either cause or increase risk for PD. Intracellular accumulations of aSyn are pathological hallmarks of PD. Taken together, reduction of aSyn production may provide a disease-modifying therapy for PD. We show that antisense oligonucleotides (ASOs) reduce production of aSyn in rodent preformed fibril (PFF) models of PD. Reduced aSyn production leads to prevention and removal of established aSyn pathology and prevents dopaminergic cell dysfunction. In addition, we address the translational potential of the approach through characterization of human SNCA-targeting ASOs that efficiently suppress the human SNCA transcript in vivo. We demonstrate broad activity and distribution of the human SNCA ASOs throughout the nonhuman primate brain and a corresponding decrease in aSyn cerebral spinal fluid (CSF) levels. Taken together, these data suggest that, by inhibiting production of aSyn, it may be possible to reverse established pathology; thus, these data support the development of SNCA ASOs as a potential disease-modifying therapy for PD and related synucleinopathies.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1172/jci.insight.135633
- Canonical
- link ↗
- Fetched
- 2026-10-27 MST
Cite this
APA
Cole, T.A., Zhao, H.T., Collier, T.J., Sandoval, I.M., Sortwell, C.E., Steece‐Collier, K., Daley, B.F., Booms, A., Lipton, J.W., Welch, M., Berman, M., Jandreski, L., Graham, D.L., Weihofen, A., Celano, S.L., Schulz, E., Cole-Strauss, A., Luna, E., Quach, D., & Mohan, A. (2021). α-Synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson’s disease. <em>JCI Insight</em>. https://doi.org/10.1172/jci.insight.135633
Vancouver
Cole TA, Zhao HT, Collier TJ, Sandoval IM, Sortwell CE, Steece‐Collier K, et al. α-Synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson’s disease. JCI Insight. 2021. doi:10.1172/jci.insight.135633.
BibTeX
@article{tracy2021Synucl,
title = {α-Synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson’s disease},
author = {Tracy A. Cole and Hien Tran Zhao and Timothy J. Collier and Ivette M. Sandoval and Caryl E. Sortwell and Kathy Steece‐Collier and Brian F. Daley and Alix Booms and Jack W. Lipton and Mackenzie Welch and Melissa Berman and Luke Jandreski and Danielle L. Graham and Andreas Weihofen and Stephanie L. Celano and Emily Schulz and Allyson Cole-Strauss and Esteban Luna and Duc Quach and Apoorva Mohan and C. Frank Bennett and Eric E. Swayze and Holly B. Kordasiewicz and Kelvin C. Luk and Katrina L. Paumier},
journal = {JCI Insight},
year = {2021},
doi = {10.1172/jci.insight.135633},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
bioRxiv (Cold Spring Harbor Laboratory) 2019
Preprint · OA
Alpha-synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson’s disease
Acta Neuropathologica 2007
Citation only
α-Synuclein pathology in the neostriatum in Parkinson’s disease
Scientific Reports 2018
Open access · CC-BY
The small molecule alpha-synuclein misfolding inhibitor, NPT200-11, produces multiple benefits in an animal model of Parkinson’s disease
2026
Citation only
Parkinson’s Disease
Annals of Neurology 2019
Open access · CC-BY
Increased Immune Activation by Pathologic α‐Synuclein in Parkinson's Disease
Parkinsonism & Related Disorders 2024
Open access · CC-BY